Results 151 to 160 of about 10,163 (201)

Nipocalimab Dose Selection in Generalized Myasthenia Gravis. [PDF]

CPT Pharmacometrics Syst Pharmacol
Valenzuela B, Neyens M, Zhu Y, Ramchandren S, Dosne AG, Leu JH, Faelens R, Ling LE, Pérez-Ruixo JJ.   +8 more
europepmc   +1 more source

Preclinical evaluation of an antibody-based companion diagnostic for CD44v6 expressing cancer. [PDF]

Nucl Med Commun
Oroujeni M, Selvaraju RK, Persson H, Dahllund L, Frejd FY, Mortensen ACL.   +5 more
europepmc   +1 more source

Does the Chimerization Process Affect the Immunochemical Properties of WNV-Neutralizing Antibody 900? [PDF]

Int J Mol Sci
Isaeva AA, Nesmeyanova VS, Shanshin DV, Ushkalenko ND, Volosnikova EA, Esina TI, Protopopova EV, Svyatchenko VA, Loktev VB, Olkin SE, Danilenko ED, Kazachinskaia EI, Shcherbakov DN.   +12 more
europepmc   +1 more source

Management of Myasthenic Crisis and Emerging Roles of Molecularly Targeted Therapies: A Narrative Review. [PDF]

Neurol Int
Takahashi S, Kinno R.
europepmc   +1 more source

Safety profile of complement C5 inhibitors and FcRn inhibitors in the treatment of myasthenia gravis: analysis of the FAERS database and disease-gene interaction network. [PDF]

Front Immunol
Wang L, Chen J, Li H, Wang L, Liu F, Jiang X.   +5 more
europepmc   +1 more source

Real-world use of efgartigimod in acetylcholine receptor antibody-positive generalized myasthenia gravis: experience from two centers in Greece and Cyprus. [PDF]

Front Neurol
Tsokkos T, Strataki E, Tzavella D, Zamba-Papanicolaou E, Kleopa KA, Zouvelou V.   +5 more
europepmc   +1 more source

Efgartigimod as Fast-Acting Rescue Therapy in Very Late-Onset Myasthenia Gravis. [PDF]

Neurol Ther
Rini N, D'Amico F, Portera V, Brighina F, Di Stefano V.   +4 more
europepmc   +1 more source

Autoimmune Neuromuscular Disorders at a Molecular Crossroad: Linking Pathogenesis to Targeted Immunotherapy. [PDF]

Int J Mol Sci
Florea AM, Luca DG, Davidescu EI, Popescu BO.   +3 more
europepmc   +1 more source

A prospective real-world study of efgartigimod in the treatment of chronic inflammatory demyelinating polyradiculoneuropathy. [PDF]

Front Immunol
Nie X, Huang G, Ma Y, Zhu G, Qi W, Zhou H, Wang W, Hao L, Guo X.   +8 more
europepmc   +1 more source